For Admin

  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012〜
  • CONTACT

Shin Nippon Biomedical Laboratories, Ltd. Translational Research Business

Japanese

A Leading Company in Nasal Drug Delivery

  • HOME
  • BUSINESS
  • TECHNOLOGY
    • Platform Technology
    • Special Analysis
    • Publication
  • APPLICATION
    • Absorption
    • Vaccination
    • Nose-to-Brain
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY

Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Widely Applicable Technology

For Absorption
For Vaccination
For Nose-to-Brain

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next

News

2019

September 17, 2019

Satsuma Pharmaceuticals, Inc. Listed on NASDAQ

August 23, 2019

Satsuma Pharmaceuticals, Inc. Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

April 25, 2019

Satsuma Pharmaceuticals, Inc. Raises $62 Million in Series B Preferred Stock Financing

February 21, 2019

Satsuma Pharmaceuticals, Inc. announces advance of lead product candidate, STS101, into Phase 3 Efficacy Trial for Acute Migraine in 2019

2023|2022|2021|2020|2019|2018|2016|2015|2014|2013|2012〜

BACK
  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY
Cookie Policy | Sitemap
© Shin Nippon Biomedical Laboratories, Ltd. All Rights Reserved.
Log out | Edit